Search clinical trials for: Anlotinib + Pemetrexed

Total 2433 results

The First Affiliated Hospital with Nanjing Medical...

Unknown

Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.

Non-squamous Non-small-cell Lung Cancer
Sichuan Cancer Hospital and Research Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Lung Cancer Metastatic

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer

Lung Cancer
Shanghai Chest Hospital

Unknown

First-line Combination Treatment Based on Anlotinib

Lung Cancer | Advanced Stage

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Adenocarcinoma | NSCLC | Squamous Cell Carcinoma
Henan Provincial People's Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC (ALTER-L025)

Non-squamous Cell Non-Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Unknown

Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

Advanced Non-squamous NSCLC

China
Hunan Province Tumor Hospital

Unknown

Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma

Lung Adenocarcinoma
Lingyu Luo

Unknown

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

Non-squamous Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
Eli Lilly and Company

Completed

A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Non-Small-Cell Lung Cancer

United Kingdom, Taiwan, Brazil, China, India, Korea, Republic of, Hong Kong
Guangzhou Institute of Respiratory Disease
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

China
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

Greece
GlaxoSmithKline

Completed

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

Lung Cancer, Non-Small Cell

United States, Italy
University of California, Davis
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cheng-Kung University Hospital

Unknown

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Non-Small Cell Lung Cancer

Taiwan
Samsung Medical Center

Recruiting

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Biliary Tract Cancer

Korea, Republic of
Akeso
Akeso Tiancheng, Inc

Terminated

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Lung Cancer Non-small Cell Stage IV

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

Non-squamous Cell Non-Small Cell Lung Cancer

China
Dutch Society of Physicians for Pulmonology and...

Completed

2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC) (NVALT10)

Carcinoma, Non-Small-Cell Lung

Netherlands
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Metastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung Cancer

China
Guangzhou Medical University

Completed

Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Lung Adenocarcinoma | Brain Metastases

China
Sichuan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer

Non-squamous Non-small-cell Lung Cancer | Anlotinib

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Mesothelioma, Malignant | Mesothelioma, Malignant Pleural | Mesothelioma Malignant Advanced

China
Shanghai Chest Hospital
Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (FOCUS-A)

Non-Small-Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Pheochromocytoma | Paraganglioma

China
Peking Union Medical College Hospital

Completed

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Paraganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, Malignant

China
Swiss Group for Clinical Cancer Research

Completed

Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

Lung Cancer

Switzerland
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
First Hospital of Shijiazhuang City

Unknown

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Carcinoma | Small Cell Lung Cancer | Lung Neoplasm

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation
Fudan University

Unknown

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Advanced Non-squamous Cell Non-small Cell Lung Cancer

China
First People's Hospital of Hangzhou
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

Recurrent High-grade Glioma

China
Peng Yuan

Completed

Anlotinib in Metastatic HER2 Negative Breast Cancer

Breast Neoplasm | Antineoplastic Agents | Anlotinib

China
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Medullary Thyroid Carcinoma

China
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Advanced Solid Tumors

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Head and Neck Cancer

United States
Guangzhou University of Traditional Chinese Medicine
Akeso Pharmaceuticals, Inc.

Recruiting

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Non-small Cell Lung Cancer

China
The First Affiliated Hospital of Guangzhou Medical...

Unknown

Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

HER2-negative Breast Cancer

China
Hunan Cancer Hospital
Fuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...

Recruiting

Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer

Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Advanced Non-squamous Non-small Cell Lung Cancer

China

3

Subscribe